Molecular links between endothelial dysfunction and neurodegeneration in Alzheimer's disease

Related Experiment Video

Updated: May 5, 2026

In Vitro Assays to Assess Blood-brain Barrier Mesh-like Vessel Formation and Disruption
10:36

In Vitro Assays to Assess Blood-brain Barrier Mesh-like Vessel Formation and Disruption

Published on: June 20, 2017

7.7K

Epameinondas Lyros, Constantinos Bakogiannis, Yang Liu

  • 1Department of Neurology, University of the Saarland, Kirrberger Str. 1, 66421 Homburg/Saar, Germany. lyrosep@upatras.gr.

Current Alzheimer Research
|November 21, 2013
PubMed

Insights

Cerebral vascular dysfunction may initiate Alzheimer's disease (AD) by impacting the blood-brain barrier and leading to neurodegeneration. Understanding these vascular links could reveal new biomarkers and therapies for AD.

Area of Science:

  • Neuroscience
  • Vascular Biology
  • Dementia Research

Background:

  • Alzheimer's disease (AD) is a leading cause of dementia, characterized by cognitive decline.
  • Emerging evidence suggests cerebral vascular dysfunction initiates neurodegenerative processes in AD.
  • Endothelial dysfunction of the blood-brain barrier disrupts amyloid-β homeostasis and allows toxic molecule infiltration.

Purpose of the Study:

  • To review molecular mechanisms linking vascular pathology and neurodegeneration in Alzheimer's disease.
  • To identify potential biomarkers and therapeutic targets for AD based on vascular and neuronal interactions.

Main Methods:

  • Literature review of existing evidence on molecular players in AD pathogenesis.
  • Analysis of studies investigating endothelial function, neuroinflammation, and apoptosis in relation to AD.
  • Synthesis of data on common pathways and molecular links between vascular and neuronal cells.

Main Results:

  • Endothelial dysfunction contributes to altered amyloid-β metabolism and neuroinflammation.
  • Shared molecular pathways, including mitochondrial integrity and apoptosis, link vascular and neuronal health.
  • Growth factors play a role in the development and maintenance of both neuronal and vascular systems.

Conclusions:

  • Vascular pathology is a critical factor in Alzheimer's disease progression.
  • Molecular players involved in vascular-neuronal interactions represent promising targets for AD biomarkers and therapies.

More Related Videos

Isolation and Functional Analysis of Arteriolar Endothelium of Mouse Brain Parenchyma06:40

Isolation and Functional Analysis of Arteriolar Endothelium of Mouse Brain Parenchyma

Published on: March 11, 2022

3.6K
Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps10:19

Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps

Published on: August 14, 2016

11.0K

Related Concept Videos

Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
42
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
29
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
35
Role of Neurotransmitters in Memory01:23

Role of Neurotransmitters in Memory

Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
 Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
2.8K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K